Thus, targeting IκBζ might constitute an attractive approach for sensitizing melanoma patients to immunotherapy, especially as IκBζ deletion would affect multiple oncogenic pathways, including NF-κB, STAT3, EZH2, and HDAC3. Here, NFKBIZ is linked to melanoma.